EAM Investors’s Cabaletta Bio CABA Stock Holding History

EAM Investors’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-55,156	Closed	-$839K	–	259
2023 Q3	$839K	Buy	+55,156	New	+$754K	0.16%	259

Other funds holding CABA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

EAM Investors's CABA Position: Q4 2023 in Review

EAM Investors sold out of Cabaletta Bio (CABA) in Q4 2023, closing a stake of 55,156 shares — an estimated $839K sold.

EAM Investors first reported a position in CABA in Q3 2023 and held it in 1 quarter. The position peaked at $839K in Q3 2023. 128 funds tracked by Wall St. Rank hold CABA as of Q4 2023.

EAM Investors reported no remaining Cabaletta Bio position as of Q4 2023 after selling out during the quarter.
EAM Investors sold 55,156 Cabaletta Bio shares in Q4 2023, an estimated $839K.
EAM Investors first reported a position in Cabaletta Bio in Q3 2023 and held it in 1 quarter.
EAM Investors's Cabaletta Bio position peaked at $839K in Q3 2023.
128 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2023.

Based on EAM Investors's 13F filing for Q4 2023, filed 14 Feb 2024.